Psyence Biomedical Ltd (PBM) saw an uptrend of 36.40% in the recent trading with $7.25 being its most recent. The current price level -98.96% lower than the highest price of $699.19 marked by the stock while trading over the past 52-weeks, whereas it is 148.13% higher than the lowest price of $2.92 the company dropped to over past 52-weeks. The latest news story on PBM appeared in (GlobeNewswire) under the title “PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares” on Jun-25-25.
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of N/A for the stock.
Psyence Biomedical Ltd Earnings – What Happened With PBM
Coming around sales and income figures on PBM Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Psyence Biomedical Ltd – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 0.08 million. PBM does have institutional investors; and they hold 46.56% of the stock.
As on 2024-06-30, ADVISORSHARES INVESTMENTS LLC was the top most holder in Psyence Biomedical Ltd (NASDAQ:PBM) with an ownership of 0.46 million shares of the company or 23.9034 of the stake worth $0.15 million. The filing also reveals CANTOR FITZGERALD, L. P. as the second largest holder in the company with a control over 17.3968 of the outstanding shares. Its stake is worth $0.1 million for having 0.34 million shares in hand.
UBS GROUP AG also came holding a key position in the company during the recent quarter and it now holds 1.1814 of the outstanding shares. With this there are now 13.0 institutions which have possession in PBM’s shares.
Key Metrics forPBM
Technical Analysis of Psyence Biomedical Ltd (NASDAQ:PBM) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Psyence Biomedical Ltd (PBM), we notice that the stock’s 20-day average volume is at 47,675 shares and 50% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 113,458 shares. And to end, PBM’s 100-day average volume is 72,701 shares with 50% of the long-term indicators pointing towards Sell for the stock.
